Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
Status:
Completed
Trial end date:
2002-08-01
Target enrollment:
Participant gender:
Summary
This study is a randomised, double-blind, parallel-group and placebo controlled study
comparing the efficacy of esomeprazole 40 mg orally qd vs. placebo and esomeprazole 20 mg
orally qd vs. placebo when given to patients on continuous use of NSAIDs, including COX-2
selective NSAIDs, for a period of 4 weeks in treatment of relief of upper GI symptoms.